Daylife Select
A point & click tool to create dynamic content portals. Learn More »
CAMBRIDGE, Mass. -- (BUSINESS WIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today presents preclinical data on the mechanism by which IMO-2125 was shown to induce immune activation through Toll-like Receptor 9 (TLR9). Full Article at Freshnews.com